US2008091004A1PendingUtilityA1

Functional and hyperfunctional siRNA directed against Bcl-2

71
Assignee: DHARMACON INCPriority: Nov 14, 2002Filed: Oct 18, 2007Published: Apr 17, 2008
Est. expiryNov 14, 2022(expired)· nominal 20-yr term from priority
Inventors:Anastasia KhvorovaAngela ReynoldsDevin LeakeWilliam MarshallStephen Scaringe
A61P 35/02A61P 37/02A61P 35/00A61P 3/10A61P 25/28C12Y 502/01008C12N 2320/10C12N 15/1135C12N 15/113C12N 15/1137A61K 31/713C12N 15/1048C12N 15/1138G16B 20/00C12N 15/1136C12N 2320/11A61P 21/00A61P 13/12C12N 2310/14C12Y 113/12007C12N 15/111G16B 20/50G16B 20/20
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing Bcl-2.

Claims

exact text as granted — not AI-modified
1 . An siRNA molecule effective at silencing Bcl-2 expression, wherein said molecule comprises a sense region and an antisense region, wherein said sense region and said antisense region together form a duplex region comprising 19-30 base pairs and said antisense region comprises a sequence that is the reverse complement of SEQ. ID NO. 308.  
     
     
         2 . The siRNA of  claim 1 , wherein said antisense region and said sense region are each 19-25 nucleotides in length.  
     
     
         3 . The siRNA of  claim 1 , wherein said antisense region and said sense region are each 19 nucleotides in length.  
     
     
         4 . The siRNA of  claim 1 , wherein said antisense region is 100% complementary to a target Bcl-2 RNA.  
     
     
         5 . The siRNA molecule of  claim 1 , wherein said siRNA molecule comprises at least one overhang region, wherein said overhang region comprises six or fewer nucleotides.  
     
     
         6 . The siRNA molecule of  claim 1  wherein said siRNA molecule comprises no overhang regions.  
     
     
         7 . The siRNA molecule of  claim 2  wherein said siRNA molecule comprises at least one overhang region, wherein said overhang region comprises six or fewer nucleotides.  
     
     
         8 . The siRNA molecule of  claim 2  wherein said siRNA molecule comprises no overhang regions.  
     
     
         9 . The siRNA molecule of  claim 3  wherein said siRNA molecule comprises at least one overhang region, wherein said overhang region comprises six or fewer nucleotides.  
     
     
         10 . The siRNA molecule of  claim 3  wherein said siRNA molecule comprises no overhang regions.

Join the waitlist — get patent alerts

Track US2008091004A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.